Investigation of healthcare-associated transmission of Mycobacterium tuberculosis among patients with malignancies at three hospitals and at a residential facility

Cancer

Volumn 101, Issue 12, 2004, Pages 2713-2721

  Malone, Joseph L ^a,e   Ijaz, Kashef ^b   Lambert, Lauren ^b   Rosencrans, Louie ^a   Phillips, Lynelle ^b   Tomlinson, Victor ^b   Arbise, Michael ^c   Moolenaar, Ronald L ^a   Dworkin, Mark S ^c   Simoes, Eduardo J ^d  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^c ILLINOIS DEPARTMENT OF PUBLIC HEALTH   (United States)

^d NATIONAL CENTER FOR CHRONIC DISEASE PREVENTION AND HEALTH PROMOTION   (United States)

^e Walter Reed Army Institute for Research   (United States)

Author keywords

Cross infection; Infection control; Leukemia complications; Residential facilities; Restriction fragment length polymorphism; Tuberculosis transmission

Indexed keywords

BACTERIAL TRANSMISSION; GENOTYPE; HEALTH CARE; HOSPITAL; HUMAN; IMMUNE DEFICIENCY; LEUKEMIA; LUNG TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; PRIORITY JOURNAL; RESIDENTIAL HOME; REVIEW; TUBERCULIN TEST;

ADOLESCENT; ADULT; AGED; CHILD; CHILD, PRESCHOOL; CONTACT TRACING; CROSS INFECTION; DISEASE TRANSMISSION, PATIENT-TO-PROFESSIONAL; DISEASE TRANSMISSION, PROFESSIONAL-TO-PATIENT; FEMALE; HOSPITALS; HUMANS; LEUKEMIA; MALE; MIDDLE AGED; MYCOBACTERIUM TUBERCULOSIS; NEOPLASMS; RESIDENTIAL FACILITIES; TUBERCULOSIS, PULMONARY;

EID: 10044234074     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.20698     Document Type: Review

References (41)

1. American Thoracic Society, Centers for Disease Control and Prevention, and Infectious Diseases Society of America. Diagnostic standards and classification of tuberculosis in adults and children. Am J Respir Crit Care Med [serial online]. 2000;161:1376-1395. Available from URL: http://www. thoracic.org/adobe/statements/tbadult1-20.pdf [accessed Nov 11, 2003].
2. Centers for Disease Control and Prevention. Targeted tuberculin testing and treatment of latent tuberculosis infection. MMWR Morb Mortal Wkly Rep [serial online]. 2000;49(No. RR-6):1-54. Available from URL: http://www.cdc.gov/mmwr/PDF/RR/RR4906.pdf [accessed Nov 11, 2003].
3. Centers for Disease Control and Prevention. Guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients. MMWR Morb Mortal Wkly Rep [serial online]. 2000;49(No. RR-10):1-128. Available from URL: http://www.cdc.gov/mmwr/PDF/RR/RR4910. pdf [accessed Nov 11, 2003].
4. Libshitz HI, Pannu HK, Elting LS, Cooksley CD. Tuberculosis in cancer patients: an update. J Thorac Imaging. 1997;12:41-46.
5. Feld R, Bodey GP, Groschel D. Mycobacteriosis in patients with malignant disease. Arch Intern Med. 1976;136:67-70.
6. Kaplan MH, Armstrong D, Rosen P. Tuberculosis complicating neoplastic disease. A review of 201 cases. Cancer. 1974;33:850-858.
7. Yuen KY, Woo PC. Tuberculosis in blood and marrow transplant recipients. Hematol Oncol. 2002;20:51-62.
8. Sanford CC. Ronald McDonald House-the house that love built. Pediatr Nurs. 1993;19:260-262.
9. Guidry JJ, Aday LA, Zhang D, Winn RJ. Cost considerations as potential barriers to cancer treatment. Cancer Pract. 1998;6:182-187.
10. Coyle D, Drummond MF. Analyzing differences in the costs of treatment across centers within economic evaluations. Int J Technol Assess Health Care. 2001;17:155-163.
11. Coyle D, Drummond MF. Costs of conventional radical radiotherapy versus continuous hyperfractionated accelerated radiotherapy (CHART) in the treatment of patients with head and neck cancer or carcinoma of the bronchus. Medical Research Council CHART Steering Committee. Clin Oncol (R Coll Radiol). 1997;9:313-321.
12. Centers for Disease Control and Prevention. Tuberculosis elimination revisited: obstacles, opportunities, and a renewed commitment. MMWR Morb Mortal Wkly Rep [serial online]. 1999;48(No. RR-9):1-13. Available from URL: http:// www.cdc.gov/mmwr/PDF/RR/RR4809.pdf [accessed Oct 30, 2004]
13. McKenna MT, McCray E, Jones JL, Onorato IM, Castro KG. The fall after the rise: tuberculosis in the United States, 1991 through 1994. Am J Public Health. 1998;88:1059-1063.
14. Centers for Disease Control and Prevention. Screening for tuberculosis and tuberculosis infection in high-risk populations. MMWR Morb Mortal Wkly Rep [serial online]. 1995; 44(No. RR-11):18-34. Available from URL: http://www. cdc.gov/mmwr/PDF/RR/RR4411.pdf [accessed Nov 11, 2003].
15. Centers for Disease Control and Prevention. Guidelines for preventing the transmission of Mycobacterium tuberculosis in healthcare facilities, 1994. MMWR Morb Mortal Wkly Rep [serial online]. 1994;43(No. RR-13):1-132. Available from URL: http://www.cdc.gov/mmwr/PDF/RR/RR4313.pdf [accessed Nov 11, 2003].
16. Centers for Disease Control and Prevention. Prevention and control of tuberculosis in facilities providing long-term care to the elderly. Recommendations of the Advisory Committee for Elimination of Tuberculosis. MMWR Morb Mortal Wkly Rep [serial online]. 1990;39(No. RR-10):7-20. Available URL: http://www.cdc.gov/mmwr/preview/mmwrhtml/ 00001711.htm [accessed Nov 11, 2003].
17. Centers for Disease Control and Prevention. Tuberculosis among residents of shelters for the homeless-Ohio, 1990. MMWR Morb Mortal Wkly Rep [serial online]. 1991;40:869-871, 877. Available from URL: http://www.cdc.gov/mmwr/ preview/mmwrhtml/00015773.htm [accessed Nov 11, 2003].
18. McKeogh MM. Tuberculosis in the hospice-a cause for concern? Palliat Med. 1997;11:469-474.
19. Centers for Disease Control and Prevention. Essential components of a tuberculosis prevention and control program. MMWR Morb Mortal Wkly Rep [serial online]. 1995;44(No. RR-11):1-16. Available from URL: http://www.cdc.gov/ mmwr/PDF/RR/RR4411.pdf [accessed Nov 11, 2003].
20. Davis YM, McCray E, Simone PM. Hospital infection control practices for tuberculosis. Clin Chest Med 1997;18:19-33.
21. McNabb SJ, Braden CR, Navin TR. DNA fingerprinting of Mycobacterium tuberculosis: lessons learned and implications for the future. Emerg Infect Dis [serial online]. 2002;8:1314-1319. Available from URL: http://www.cdc.gov/ ncidod/EID/vol8no11/02-0402.htm [accessed Nov 11, 2003].
22. Castro KG, Jaffe HW. Rationale and methods for the National Tuberculosis Genotyping and Surveillance Network. Emerg Infect Dis [serial online]. 2002;8:1188-1191. Available from URL: http://www.cdc.gov/ncidod/EID/vol8no11/ 020408.htm [accessed Nov 11, 2003].
23. Ijaz K, Yang Z, Matthews HS, Bates JH, Cave MD. Mycobacterium tuberculosis transmission between cluster members with similar fingerprint patterns. Emerg Infect Dis [serial online]. 2002;8:1257-1259. Available from URL: http: //www. cdc.gov/ncidod/EID/vol8no11/02-0284.htm [accessed Nov 11, 2003].
24. McElroy PD, Sterling TR, Driver CR, et al. Use of DNA fingerprinting to investigate a multiyear, multistate tuberculosis outbreak. Emerg Infect Dis [serial online]. 2002;8:1252-1256. Available from URL: http://www.cdc.gov/ ncidod/EID/vol8no11/02-0424.htm [accessed Nov 11, 2003].
25. Bennett DE, Onorato IM, Ellis BA, et al. DNA fingerprinting of Mycobacterium tuberculosis isolates from epidemiologically linked case pairs. Emerg Infect Dis [serial online]. 2002;8:1224-1229. Available from URL: http://www.cdc.gov/ ncidod/EID/vol8no11/02-0420.htm [accessed Nov 11, 2003].
26. Behr MA, Hopewell PC, Paz EA, Kawamura LM, Schecter GF, Small PM. Predictive value of contact investigation for identifying recent transmission of Mycobacterium tuberculosis. Am J Respir Crit Care Med. 1998;158:465-469.
27. Shinnick TN, Good RC. Diagnostic mycobacteriology laboratory practices. Clin Infect Dis. 1995;21:291-299.
28. van Embden JD, Cave MD, Crawford JT, et al. Strain identification of Mycobacterium tuberculosis by DNA finger-printing: recommendations for a standardized methodology. J Clin Microbiol. 1993;31:406-409.
29. Crawford JT, Braden CR, Schable BA, Onorato IM. National Tuberculosis Genotyping and Surveillance Network: design and methods. Emerg Infect Dis [serial online]. 2002;8:1192-1196. Available from URL: http://www.cdc.gov/ ncidod/ EID/vol8no11/02-0296.htm [accessed Nov 11, 2003].
30. Kamerbeek J, Schouls L, Kolk A, et al. Simultaneous detection and strain differentiation of Mycobacterium tuberculosis for diagnosis and epidemiology. J Clin Microbiol. 1997;35:907-914.
31. Centers for Disease Control and Prevention. Treatment of tuberculosis: American Thoracic Society, CDC, and Infectious Diseases Society of America. MMWR Morb Mortal Wkly Rep [serial online]. 2003;52(No. RR-11):1-77. Available from URL: http://www.cdc.gov/mmwr/PDF/RR/RR5211.pdf [accessed Nov 11, 2003].
32. Centers for Disease Control and Prevention. Trends in tuberculosis morbidity-United States, 1992-2002. MMWR Morb Mortal Wkly Rep [serial online]. 2003;52:217-220, 222. Available from URL: http://www.cdc.gov/mmwr/PDF/wk/ mm5211.pdf [accessed Nov 11, 2003].
33. Dooley KE, Golub J, Goes FS, Merz WG, Sterling TR. Empiric treatment of community-acquired pneumonia with fluoroquinolones, and delays in the treatment of tuberculosis. Clin Infect Dis. 2002;34:1607-1612.
34. Fridkin SK, Manangan L, Bolyard E, Jarvis WR. SHEA-CDC TB survey. Part I: status of TB infection control programs at member hospitals, 1989-1992. Society for Healthcare Epidemiology of America. Infect Control Hosp Epidemiol. 1995;16:129-134.
35. Mazurek GH, Villarino ME. Guidelines for using the QuantiFERON-TB test for diagnosing latent Mycobacterium tuberculosis infection. Centers for Disease Control and Prevention. MMWR Morb Mortal Wkly Rep [serial online]. 2003; 52(No. RR-2):15-18. Available from URL: http:// www.cdc.gov/mmwr/PDF/RR/RR5202.pdf [accessed Nov 11, 2003].
36. Rai KR, Freter CE, Mercier RJ, et al. Alemtuzumab in previously treated chronic lymphocytic leukemia patients who also had received fludarabine. J Clin Oncol. 2002;20:3891-3897.
37. Willemze R, Richel DJ, Falkenburg JH, et al. In vivo use of Campath-1G to prevent graft-versus -host disease and graft rejection after bone marrow transplantation. Bone Marrow Transplant. 1992;9:255-261.
38. Abad S, Gyan E, Moachon L, et al. Tuberculosis due to Mycobacterium bovis after alemtuzumab administration. Clin Infect Dis [serial online]. 2003;37:e27-e28. Available from URL: http://www.journals.uchicago.edu/CID/ journal/issues/v37n2/30481/30481.html [accessed Nov 11, 2003].
39. Keane J, Gershon S, Wise RP, et al. Tuberculosis associated with infliximab, a tumor necrosis factor α-neutralizing agent. N Engl J Med. 2001;345:1098-1104.
40. Greenaway C, Menzies D, Fanning A, Grewal R, Yuan L, FitzGerald JM. Delay in diagnosis among hospitalized patients with active tuberculosis-predictors and outcomes. Canadian Collaborative Group in Nosocomial Transmission of Tuberculosis. Am J Respir Crit Care Med. 2002;165:927-933.
41. Smith PW, Rusnak PG. Infection prevention and control in the long-term-care facility. SHEA Long-Term-Care Committee and APIC Guidelines Committee. Am J Infect Control. 1997;25:488-512.